DelSiTech Ltd, the leading silica drug delivery technology company, based in Turku, Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology.
The collaboration joins key European innovations in biomaterials and the pinnacle of Chinese drug research innovation emerging from the prestigious J. Michael Bishop Institute of Cancer Research, mentored by the year 1989 Noble prize winner Professor J. Michael Bishop.
While numerous therapies have shown significant promise in oncology, many still face difficult challenges that can be conveniently addressed by formulation technologies. While otherwise effective, shortcomings in solubility, bioavailability, pharmacokinetics paired with a narrow therapeutic index, practicality, side-effects and instability of the effective treatment can result in patients with life-threatening circumstances left with fewer treatment options.
Dr. Lasse Leino, CEO of DelSiTech commented: “We are excited and proud to be collaborating with our innovative and forward-thinking partner in China to develop practical solutions to treat cancer patients world-wide. This new collaboration highlights the versatility of our Silica Matrix platform which is suitable for therapeutic applications in oncology. We estimate that in the future, many treatment modalities for cancer diseases will be centred on long-acting controlled release products. Recently, we presented data on how widely used anticancer peptides goserelin and triptorelin can be formulated into Silica Matrix to produce injectable long-acting products.”
Dr. Dun Yang PhD, Founder, President, and CEO of Anticancer Bioscience commented: “We are excited to be working with DelSiTech. The delivery of our cancer therapeutics using DelSiTech’s proprietary drug delivery technology will enable us to explore novel mechanisms of action and new indications for our therapeutics. We recognize the need to partner with companies like DelSiTech who specialise in drug delivery, to maximize patient outcomes.”